Adamas Pharmaceuticals Inc (ADMS)

Common Stock

8.22  +0.06 (+0.74%)

After market: 8.3 +0.08 (+0.97%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

Adamas Pharmaceuticals Inc

NASDAQ:ADMS (11/23/2021, 3:18:38 PM)

After market: 8.3 +0.08 (+0.97%)

8.22

+0.06 (+0.74%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap374.98M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ADMS Daily chart

Company Profile

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. The company is headquartered in Emeryville, California and currently employs 138 full-time employees. The company went IPO on 2014-04-10. The firm is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company’s portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson’s disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer’s type.

Company Info

Adamas Pharmaceuticals Inc

1900 Powell St Ste 1000

Emeryville CALIFORNIA 94608

P: 15104503554.0

CEO: Neil F. McFarlane

Employees: 138

Website: https://adamaspharma.com/

ADMS News

News Image2 years ago - Halper Sadeh LLPSHAREHOLDER INVESTIGATION: Halper Sadeh LLP is Investigating the Following Companies - BCML, GWB, ABTX, ESBK, ADMS, ACBI

/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: BayCom Corp (NASDAQ: BCML)...

News Image2 years ago - WeissLaw LLPSHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, ADMS, and ACBI Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

News Image2 years ago - Halper Sadeh LLPSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ROG, RRD, XLRN, ADMS; Shareholders are Encouraged to Contact the Firm

/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Rogers Corporation (NYSE: ROG)...

News Image2 years ago - WeissLaw LLPSHAREHOLDER ALERT: WeissLaw LLP Reminds OMP, ADMS, ACBI and ECHO Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

News Image2 years ago - The Business JournalsEast Bay drug maker's potential sale brings lawsuits, job cuts
News Image2 years ago - Zacks Investment ResearchWill Adamas Pharmaceuticals (ADMS) Report Negative Q3 Earnings? What You Should Know

Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ADMS Twits

Here you can normally see the latest stock twits on ADMS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example